Treatment and outcomes of patients with evolving myocardial infarction: Experiences from the SYNERGY trial

European Heart Journal

Volumn 28, Issue 9, 2007, Pages 1079-1084

  Miller, Chadwick D ^a   Banerjee, Anindita ^b   Mahaffey, Kenneth W ^c   Kontos, Michael C ^d   Fermann, Gregory ^e   Pollack Jr , Charles V ^f   Antman, Elliott ^g   Aylward, Philip ^h   Goodman, Shaun G ⁱ   Santos, Renato ^a   Ferguson, James J ^j   Califf, Robert M ^c   Hoekstra, James W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f PENNSYLVANIA HOSPITAL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h FLINDERS MEDICAL CENTRE   (Australia)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j TEXAS HEART INSTITUTE   (United States)

more..

Author keywords

Evolving myocardial infarction; Initial treatment; Outcomes; Troponin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TROPONIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANK SUM TEST; REVASCULARIZATION; RISK ASSESSMENT; ST SEGMENT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; FEMALE; FIBRINOLYTIC AGENTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; TREATMENT OUTCOME; TROPONIN;

EID: 34548317098     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm016     Document Type: Article

References (17)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr ; American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina.. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-1374.
2. The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513.
3. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-1349.
4. Green GB, Beaudreau RW, Chan DW, DeLong D, Kelley CA, Kelen GD. Use of troponin T and creatine kinase-MB subunit levels for risk stratification of emergency department patients with possible myocardial ischemia. Ann Emerg Med 1998;31:19-29.
5. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
6. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43-48.
7. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-1762.
8. SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
9. The SYNERGY Executive Committee trial: study design and rationale. Am Heart J 2002;143:952-960.
10. Roe MT, Peterson ED, Pollack CV Jr, Newby LK, Li Y, Christenson RH, Peacock WF, Fesmire FM, Diercks D, Kirk JD, Smith SC Jr, Ohman EM, Gibler WB ; CRUSADE Investigators. Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med 2005;45:355-362.
11. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000;101:2557-2567.
12. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-842.
13. Bartholomew BA, Sheps DS, Monroe S, McGorray S, Smith K, Pepine CJ. A population-based evaluation of the thrombolysis in myocardial infarction risk score for unstable angina and non-ST elevation myocardial infarction. Clin Cardiol 2004;27:74-78.
14. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EE III, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994;90:613-622.
15. Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2005;46:906-919.
16. Hoekstra JW, Roe MT, Peterson ED, Menon V, Mulgund J, Pollack CV, Miller C, Palabrica T, Harrington RA, Ohman EM, Gibler WB. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med 2005;12:431-438.
17. Ohman EM, Roe MT, Smith SC Jr, Brindis RG, Christenson RH, Harrington RA, Gibler WB, Peterson ED; CRUSADE Investigators. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J 2004;148(Suppl. 5): S34-S39.